Table 3 Cancer PDX models in therapeutic approaches
From: Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Tumor histotype | PDX model | Treatment/molecular alterations | Response rate (RR) | Ref. |
|---|---|---|---|---|
Breast cancer | Orthotopic | Docetaxel, 5-fluorouracil, trastuzumab | 71% | [125] |
Docetaxel, doxorubicin, trastuzumab + Lap | 100% | [126] | ||
Colorectal cancer | Heterotopic | Cetuximab, panitumumab | 100% | [80] |
Heterotopic | WT KRAS | 100% responded to cetuximab | [127] | |
Heterotopic | Oxaliplatin | 92% | [79] | |
Ovarian cancer | Heterotopic | Cisplatin | 81% | [128] |
Heterotopic | Doxorubicin, cyclophosphamide, 5-fu | 0–27% | [42] | |
Gastric cancer | Heterotopic | Regorafenib | 96% | [129] |
Non-small cell lung cancer | Heterotopic | EGFR mutated | 10% responded to gefitinib | [130] |
Pancreatic ductal adenocarcinoma (PDAC) | Heterotopic | Gemcitabine | 17% | [131] |